NCT05481645 2026-01-09
Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Terminated
Clinical Trials
26 trialsNCT03860844 2025-09-09
ISAKIDS
Sanofi
Phase 2 Terminated
NCT03646123 2025-08-28
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT05092360 2025-08-28
ARTISTRY-7
Mural Oncology, Inc
Phase 3 Terminated
NCT03034304 2025-07-24
A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
HRYZ Biotech Co.
Phase 1 Terminated
NCT04203641 2025-05-06
L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
Helix BioPharma Corporation
Phase 1/2 Terminated
NCT05100628 2025-01-06
A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma
Noxopharm Limited
Phase 1 Terminated
NCT02626455 2024-12-11
CHRONOS-4
Bayer
Phase 3 Terminated
NCT04996004 2024-12-11
TTI-621-03
Pfizer
Phase 2 Terminated
NCT03145558 2024-11-22
TATE
Teclison Ltd.
Phase 2 Terminated
NCT04790903 2024-07-11
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
Phase 1 Terminated
NCT05207514 2024-05-17
Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer
Samyang Biopharmaceuticals Corporation
Phase 3 Terminated
NCT05622058 2023-02-27
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
Aileron Therapeutics, Inc.
Phase 1 Terminated
NCT01464593 2022-10-13
ABLATE
Imunon
Phase 2 Terminated
NCT01387932 2021-11-30
HiQuality
Merit Medical Systems, Inc.
Phase 3 Terminated
NCT01220128 2021-05-25
INDUCT
GlaxoSmithKline
Phase 2 Terminated
NCT01697293 2020-09-24
PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer
Prescient Therapeutics, Ltd.
Phase 1/2 Terminated
NCT01287741 2019-04-12
A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Hoffmann-La Roche
Phase 3 Terminated
NCT02855359 2019-03-11
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT02255110 2018-12-14
A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Merck KGaA, Darmstadt, Germany
Phase 2 Terminated
NCT00960063 2018-08-27
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT01925612 2018-06-21
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Seagen Inc.
Phase 2 Terminated
NCT00883116 2017-03-09
IXAMPLE2
R-Pharm
Phase 3 Terminated
NCT02107378 2016-11-30
Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Phase 2 Terminated
NCT01131364 2014-02-25
Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients
Philogen S.p.A.
Phase 1/2 Terminated
NCT00461344 2008-04-03
Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
Sanofi
Phase 2 Terminated